bluebird bio Valuation
Is BLUE * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of BLUE * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: BLUE * (MX$10) is trading below our estimate of fair value (MX$195.21)
Significantly Below Fair Value: BLUE * is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BLUE *?
Key metric: As BLUE * is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is BLUE *'s PS Ratio? | |
|---|---|
| PS Ratio | 1.4x |
| Sales | US$53.12m |
| Market Cap | US$71.94m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 7.1x |
| Enterprise Value/EBITDA | -1.4x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does BLUE *'s PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 20.7x | ||
GBIO Generation Bio | 5.1x | -15.6% | US$96.2m |
BCAB BioAtla | 6.9x | 56.9% | US$80.3m |
COYA Coya Therapeutics | 11.6x | 22.7% | US$106.6m |
XFOR X4 Pharmaceuticals | 59.1x | 64.3% | US$60.1m |
BLUE * bluebird bio | 1.4x | 41.5% | Mex$71.9m |
Price-To-Sales vs Peers: BLUE * is good value based on its Price-To-Sales Ratio (1.4x) compared to the peer average (19.2x).
Price to Sales Ratio vs Industry
How does BLUE *'s PS Ratio compare vs other companies in the Global Biotechs Industry?
Price-To-Sales vs Industry: BLUE * is good value based on its Price-To-Sales Ratio (1.4x) compared to the Global Biotechs industry average (9x).
Price to Sales Ratio vs Fair Ratio
What is BLUE *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 1.4x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate BLUE *'s Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
CSPC Pharmaceutical Group
HK$69.4b
An investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People’s Republic of China, other Asian regions, North America, Europe, and internationally.
1093 N
HK$15.69
7D
0%
1Y
-27.0%
Exact Sciences
US$13.1b
Provides cancer screening and diagnostic test products in the United States and internationally.
EXAS *
US$872.00
7D
0%
1Y
n/a
Incyte
US$13.8b
A biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally.
INCY *
US$1,486.00
7D
0%
1Y
n/a